Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;30(8):1113-1119.
doi: 10.1016/j.jsps.2022.06.002. Epub 2022 Jun 13.

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence

Wedad H Alotaibi  1 , Majd M Alhamdan  1 , Bander Balkhi  2   3
Affiliations

Cost-effectiveness of Ribociclib in HER2- negative breast cancer: A synthesis of current evidence

Wedad H Alotaibi et al. Saudi Pharm J. 2022 Aug.

Abstract

Background: The main aim of this study was to investigate the cost-effectiveness of Ribociclib in the treatment of patients with breast cancer by assessing the published evidence.

Method: A systematic review of the published literature was conducted to identify the economic evaluations/cost-effectiveness study of Ribociclib. In this study, several databases were inspected, including PubMed, NHS Economic Evaluation, Cochran, and Scopus. Studies were eligible if they assessed the cost-effectiveness of Ribociclib and reported incremental cost-effectiveness ratio (ICER). The study was performed and conducted following the PRISMA reporting guidelines.

Results: Of 70 studies identified, 8 articles meet our inclusion criteria. The cost-effectiveness threshold varied from $24,144.18 in Spain to $198,000/QALY in the USA. Moreover, the result demonstrated that the mean ICER varied across different countries $1,863.47/QALY in Spain and $813,132/QALY in the USA.

Conclusion: Among all CDK4/6 inhibitors medications, current evidence indicated that the use of Ribociclib for HER2- negative breast cancer management was beneficial and considered to be cost-effective. Future research is needed to investigate the role of Ribociclib in long-term treatment.

Keywords: Breast cancer; CDK4/6 inhibitors; Cost-effectiveness; Economics evaluation; Ribociclib; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Fig. 1
Fig. 1
Process of the systematic literature search, according to the preferred reporting items for systematic review and meta-analyses.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Barbieri M., Drummond M., Rutten F., Cook J., Glick H.A., Lis J., Reed S.D., Sculpher M., Severens J.L. What do international pharmacoeconomic guidelines say about economic data transferability? Value in Health. 2010;13(8):1028–1037. - PubMed
    1. Blumen H., Fitch K., Polkus V. Comparison of treatment costs for breast cancer, by tumor stage and type of service. Am. Health Drug Benefits. 2016;9:23. - PMC - PubMed
    1. Diaby V., Tawk R., Sanogo V., Xiao H., Montero A.J. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res. Treat. 2015;151(1):27–40. - PMC - PubMed
    1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015;136(5):E359–E386. - PubMed
    1. Ferreira, L., Ferreira, P., 2014. Health state values and country-specific value sets. Encyclopedia of Quality of Life and Well-Being Research. Dordrecht, Netherlands: Springer, pp. 2744–2749.